The American Society of Hypertension (“ASH”) is the largest organization in the United States devoted exclusively to hypertension and related cardiovascular diseases. It is anticipated that more than 4,000 internists, nephrologists, cardiologists and specialists in cardiovascular medicine from around the world will attend the annual meeting in order to review and consider the latest research in the fields of high blood pressure and vascular, cardiac and fluid control mechanisms. HDI will be demonstrating its painless, non-invasive, FDA cleared CVProfilor^® DO-2020 Cardiovascular Profiling System during the exhibition.

“The value of these abstract presentations to our world marketing effort cannot be overstated,” said Greg H. Guettler, President. “The use of our cardiovascular profiling technology in these published cardiovascular studies adds considerable credibility to our current Company bibliography of more than 135 published works regarding our blood pressure waveform methodology and our cardiovascular profiling technology. These 11 abstracts provide additional scientific merit to the value of HDI’s technology in disease assessment and help increase product awareness among physicians worldwide.”

The technology used in the clinical studies featured in the platform and poster sessions is the only commercially available research product (that is, the HDI/PulseWave™ CR-2000 Research System) and FDA cleared medical device (that is, the CVProfilor^® DO-2020 System) which can provide both large and small artery elasticity indices by means of a simple, painless and non-invasive procedure.

Dr. Nathaniel Winer and his colleagues at the Department of Medicine, SUNY Downstate Medical Center in Brooklyn, will have an oral presentation at the meeting which demonstrates that a marked improvement in arterial elasticity occurs when diabetic hypertensive patients receive a combination of drugs. This study was conducted using the HDI/PulseWave™ CR-2000 CardioVascular Profiling System. Researchers from the Cardiology Department, State University of N.Y. (Buffalo), who used the HDI/PulseWave™ CR-2000 Research System, will show in their poster session that ingesting caffeine reduces small artery elasticity, but not large artery elasticity, and that long-term use of caffeine may contribute to the development of hypertension and, therefore, an increased incidence of cardiovascular disease. Also using the HDI/PulseWave™ CR-2000 Research System, another poster session by clinical investigators from the Medical College of Georgia will provide data to show that there is no statistical difference in results when the blood pressure cuff and the HDI Arterial PulseWave™ Sensor are placed on either the same arm or on opposite arms.

Employing the HDI pulse contour analysis technology, physicians from the Department of Cardiology at XiAn Jiaotong University in China (the first U.S. published abstract from Chinese physician investigators) will present a poster on the normal ranges of large and small artery elasticity indices for 204 healthy Chinese subjects (97 men, mean age 45 15 years). Also using the HDI/PulseWave™ CR-2000 Research System, clinical researchers from the Hypertension and Vascular Disease Center at the Wake Forest University School of Medicine (Winston-Salem, NC) will present three posters at the annual ASH meeting: one will show data that suggests a potential contribution by severe distal aortic disease to the pathogenesis of hypertension; another concludes that non-invasive hemodynamic monitoring which includes a determination of arterial elasticity may be important in guiding therapeutic approaches for the management of hypertensive patients; and a third will offer data to demonstrate good correlation for stroke volume, cardiac output and systemic vascular resistance between HDI’s method and another firm’s machine.

Prior to and following a structured cardiac rehabilitation program, patients with coronary artery disease were evaluated for large and small artery elasticity using the HDI/PulseWave™ CR-2000 Research System. This poster session by physicians from Mount Sinai School of Medicine and Lenox Hill Hospital (New York City) will show that aerobic exercise in these older patients enhanced small artery elasticity most likely due to improved endothelial function. Stephen P. Glasser, M.D., and his colleagues from the University of Minnesota, Division of Epidemiology (Minneapolis) will have a poster at the meeting which describes the functional and structural effects of doxazosin on large and small artery elasticity as determined by the HDI/PulseWave™ CR-2000 Research System. Using this same System, data from a subset of subjects included in the large, multi-site Trial of Preventing Hypertension (“TROPHY”) Study will be presented in a poster to show that leptin is associated with impaired small artery distensibility in patients with high normal blood pressure.

Clinical investigators from the Department of Medicine, Cardiology Division at the University of Minnesota Medical School (Minneapolis) have employed HDI’s CVProfilor^® DO-2020 System as part of a clinical testing array to evaluate more than 300 individuals (60% male, age range 21-79 years) in the Rasmussen Center for Cardiovascular Disease Prevention. The poster to be displayed by Jay N. Cohn, M.D., and his colleagues will show that vascular and/or cardiac abnormalities were detected in over 60% of the patients, most of whom were unaware of and untreated for their disease, suggesting that there is a marked deficiency in the early detection, and therefore the treatment of, cardiovascular disease.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company’s 2001 Annual Report on Form 10-KSB under the caption “Risk Factors,” as well as others not now anticipated.

CVProfilor is a registered trademark of Hypertension Diagnostics, Inc.
  
Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Investor Relations: Jens Dalsgaard and Tony Altavilla,
Managing Directors
Redwood Consultants, LLC
Mill Valley, CA 94941
415-380-0500

Contact: Greg H. Guettler, President